Home
NICE Guidance
Conditions and diseases
Cancer
Breast cancer
Breast cancer
Savings and productivity
Register as a stakeholder
Show sections
Do not do
Do not perform sentinel lymph node biopsy (SLNB) routinely in patients with a preoperative diagnosis of ductal carcinoma in situ (DCIS) who are having breast conserving surgery, unless they are considered to be at a high risk of invasive disease .
February 2009
Do not offer further axillary treatment to patients found to have only isolated tumour cells in their sentinel lymph nodes. These patients should be regarded as lymph node-negative.
February 2009
Do not routinely assess progesterone receptor status of tumours in patients with invasive breast cancer.
February 2009
Do not offer adjuvant ovarian ablation/suppression to premenopausal women with estrogen receptor (ER)-positive early invasive breast cancer who are being treated with tamoxifen and, if indicated, chemotherapy.
February 2009
Do not offer adjuvant tamoxifen after breast conserving surgery to patients with ductal carcinoma in situ (DCIS).
February 2009
Do not offer paclitaxel as an adjuvant treatment for lymph node-positive breast cancer.
February 2009
Do not offer a dual energy x-ray absorptiometry (DEXA) scan to patients with early invasive breast cancer who are receiving tamoxifen alone, regardless of pretreatment menopausal status.
February 2009
Do not offer radiotherapy following mastectomy to patients with early invasive breast cancer who are at low risk of local recurrence (for example, most patients who are lymph node-negative).
February 2009
Do not offer adjuvant radiotherapy to the axilla or supraclavicular fossa to patients with early breast cancer who have been shown to be histologically lymph node-negative.
February 2009
Do not offer adjuvant radiotherapy to the axilla after axillary lymph node dissection (ALND) for early breast cancer.
February 2009
Full List
Guidance
Resources
Savings and productivity
Local practice